<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6563">
  <stage>Registered</stage>
  <submitdate>23/05/2017</submitdate>
  <approvaldate>23/05/2017</approvaldate>
  <nctid>NCT03197766</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia</studytitle>
    <scientifictitle>A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-003836-11</secondaryid>
    <secondaryid>111-301</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Achondroplasia</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMN 111
Treatment: drugs - Placebo

Experimental: Active BMN 111 - Daily subcutaneous injection of 15 micrograms per kilogram BMN111

Placebo Comparator: Placebo - Daily subcutaneous injection of placebo


Treatment: drugs: BMN 111
Subcutaneous injection of 15 µg/kg of BMN 111 daily

Treatment: drugs: Placebo
Subcutaneous injection of 15 µg/kg of placebo daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in mean Annualized Growth Velocity - Evaluate change from baseline in mean annualized growth velocity at 52 weeks in subjects treated with BMN 111 compared with control subjects in the placebo group</outcome>
      <timepoint>one year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in height Z-scores - Evaluate change from baseline in height Z-score in subjects treated with BMN 111 compared with control subjects in the placebo group at 52 weeks</outcome>
      <timepoint>one year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in upper to lower segment body ratio - Evaluate change from baseline in mean upper:lower segment body ratio in subjects treated with BMN 111 compared with control subjects in the placebo group at 52 weeks</outcome>
      <timepoint>one year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Adverse Events [Safety and Tolerability] - The number of subjects who reported at least one adverse event</outcome>
      <timepoint>54 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Characterize maximum concentration (Cmax) of BMN 111 in plasma</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Characterize the area under the plasma concentration time-curve from time 0 to infinity (AUC0-8)</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Characterize the area under the plasma concentration time-curve from time 0 to the last measurable concentration (AUC0-t)</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Characterize the elimination half-life of BMN 111 (t½)</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Characterize the apparent clearance of drug</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Characterize the apparent volume of distribution based upon the terminal phase (Vz/F)</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Characterize the amount of time BMN 111 is present at maximum concentration (Tmax)</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          -  Parent(s) or guardian(s) consent

          -  5 to &lt; 17 years old

          -  ACH, documented and confirmed by genetic testing

          -  At least a 6-month period of pretreatment growth assessment in Study 111-901 before
             study entry

          -  If sexually active, willing to use a highly effective method of contraception

          -  Ambulatory and able to stand without assistance</inclusivecriteria>
    <inclusiveminage>5</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>17</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Hypochondroplasia or short stature condition other than ACH

          -  Have any of the following:

               -  Hypothyroidism or hyperthyroidism

               -  Insulin-requiring diabetes mellitus

               -  Autoimmune inflammatory disease

               -  Inflammatory bowel disease

               -  Autonomic neuropathy

          -  History of any of the following:

               -  Renal insufficiency defined as serum creatinine &gt; 2 mg/dL

               -  Chronic anemia

          -  Cardiac or vascular disease

          -  Have an unstable condition likely to require surgical intervention during the study
             (including progressive cervical medullary compression or severe untreated sleep apnea)

          -  Evidence of growth plate closure (proximal tibia, distal femur)

          -  Treated with growth hormone, insulin-like growth factor 1 (IGF-1), or anabolic
             steroids in the previous 6 months or treatment greater than 6 months at any time

          -  Greater than 1 month treatment with oral corticosteroids (low-dose ongoing inhaled
             steroid for asthma, or intranasal steroids, are acceptable) in the previous 12 months

          -  Planned or expected to have limb-lengthening surgery during the study period. Subjects
             with previous limb- lengthening surgery may enroll if surgery occurred at least 18
             months prior to the study and healing is complete without sequelae.

          -  Planned or expected bone-related surgery (ie. surgery involving disruption of bone
             cortex), during the study period. Subjects with previous bone-related surgery may
             enroll if surgery occurred at least 12 months prior to the study and healing is
             complete without sequelae.

          -  Had a fracture of the long bones or spine within 6 months prior to screening

          -  History of severe untreated sleep apnea

          -  New initiation of sleep apnea treatment (e.g. CPAP or sleep apnea-mitigating surgery)
             in the previous 2 months prior to screening

          -  History of hip surgery or hip dysplasia atypical for achondroplastic subjects

          -  History of clinically significant hip injury in the 30 days prior to screening

          -  History of slipped capital femoral epiphysis or avascular necrosis of the femoral head

          -  Abnormal findings on baseline clinical hip exam or imaging assessments that are
             determined to be clinically significant

          -  Concurrent disease or condition that would interfere with study participation or
             safety evaluations, for any reason

          -  Condition or circumstance that places the subject at high risk for poor treatment
             compliance or for not completing the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>12/12/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>110</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Murdoch Children's Research Institute - Parkville</hospital>
    <postcode>3052 - Parkville</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>BioMarin Pharmaceutical</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for
      the treatment of children with Achondroplasia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03197766</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director, MD</name>
      <address>BioMarin Pharmaceutical</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>